Molecule Information

General Information of the Molecule (ID: Mol01202)
Name
Aminoglycoside N(3)-acetyltransferase (AACC2) ,Pseudomonas aeruginosa
Molecule Type
Protein
Gene Name
AAC(3)-IIc
Sequence
MHTRKAITEALQKLGVQTGDLLMVHASLKAIGPVEGGAETVVAALRSAVGPTGTVMGYAS
WDRSPYEETRNGARLDDKTRRTWPPFDPATAGTYRGFGLLNQFLVQAPGARRSAHPDASM
VAVGPLAETLTEPHKLGHALGEGSPVERFVRLGGKALLLGAPLNSVTALHYAEAVADIPN
KRRVTYEMPMLGSNGEVAWKTASDYDSNGILDCFAIEGKPDAVETIANAYVKLGRHREGV
VGFAQCYLFDAQDIVTFGVTYLEKHFGTTPIVPAHEVAECSCEPSG
    Click to Show/Hide
        Click to Show/Hide the Complete Species Lineage
Kingdom: N.A.
Phylum: Proteobacteria
Class: Gammaproteobacteria
Order: Pseudomonadales
Family: Pseudomonadaceae
Genus: Pseudomonas
Species: Pseudomonas aeruginosa
Type(s) of Resistant Mechanism of This Molecule
  DISM: Drug Inactivation by Structure Modification
Drug Resistance Data Categorized by Drug
Approved Drug(s)
3 drug(s) in total
Click to Show/Hide the Full List of Drugs
Gentamicin
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Disease Class: Bacterial infection [1], [2]
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
 Disease Info 
Resistant Drug Gentamicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Folliculitis [1], [2]
Resistant Disease Folliculitis [ICD-11: 1B74.0]
 Disease Info 
Resistant Drug Gentamicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Pseudomonas aeruginosa infection [1], [2]
Resistant Disease Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z]
 Disease Info 
Resistant Drug Gentamicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Corneal ulcers [1], [2]
Resistant Disease Corneal ulcers [ICD-11: 9A76.0]
 Disease Info 
Resistant Drug Gentamicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Netilmicin
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Disease Class: Bacterial infection [1], [2]
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
 Disease Info 
Resistant Drug Netilmicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Folliculitis [1], [2]
Resistant Disease Folliculitis [ICD-11: 1B74.0]
 Disease Info 
Resistant Drug Netilmicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Pseudomonas aeruginosa infection [1], [2]
Resistant Disease Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z]
 Disease Info 
Resistant Drug Netilmicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Corneal ulcers [1], [2]
Resistant Disease Corneal ulcers [ICD-11: 9A76.0]
 Disease Info 
Resistant Drug Netilmicin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Tobramycin
Click to Show/Hide
Drug Resistance Data Categorized by Their Corresponding Mechanisms
       Drug Inactivation by Structure Modification (DISM) Click to Show/Hide
Disease Class: Bacterial infection [1], [2]
Resistant Disease Bacterial infection [ICD-11: 1A00-1C4Z]
 Disease Info 
Resistant Drug Tobramycin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Folliculitis [1], [2]
Resistant Disease Folliculitis [ICD-11: 1B74.0]
 Disease Info 
Resistant Drug Tobramycin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Pseudomonas aeruginosa infection [1], [2]
Resistant Disease Pseudomonas aeruginosa infection [ICD-11: 1A00-1C4Z]
 Disease Info 
Resistant Drug Tobramycin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
Disease Class: Corneal ulcers [1], [2]
Resistant Disease Corneal ulcers [ICD-11: 9A76.0]
 Disease Info 
Resistant Drug Tobramycin
 Drug Info 
Molecule Alteration Expression
Up-regulation
Experimental Note Identified from the Human Clinical Data
In Vitro Model Escherichia coli ATCC 25922 1322345
Pseudomonas aeruginosa ATCC 27853 287
Pseudomonas aeruginosa isolates 287
Staphylococcus aureus ATCC 25923 1280
Experiment for
Molecule Alteration		 Whole genome sequence assay
Experiment for
Drug Resistance		 Agar dilution method assay
Mechanism Description Various aminoglycoside modifying enzymes were associated with overlapping phenotypes: 36.5% strains produced AAC(6')-I with either a serine (GEN-TOB-NET) or a leucine (TOB-NET-AMk) at position 119, or both variants (GEN-TOB-NET-AMk); 21.2% expressed ANT(2")-I (GEN-TOB), 7.7% AAC(3)-II (GEN-TOB-NET), 5.8% AAC(3)-I (GEN) and 1.9% AAC(6')-II (GEN-TOB-NET-AMk) or AACA7 (TOB-NET-AMk).
References
Ref 1 Beta-lactam and aminoglycoside resistance rates and mechanisms among Pseudomonas aeruginosa in French general practice (community and private healthcare centres). J Antimicrob Chemother. 2008 Aug;62(2):316-23. doi: 10.1093/jac/dkn174. Epub 2008 May 8.
Ref 2 Molecular genetics of aminoglycoside resistance genes and familial relationships of the aminoglycoside-modifying enzymes. Microbiol Rev. 1993 Mar;57(1):138-63. doi: 10.1128/mr.57.1.138-163.1993.

If you find any error in data or bug in web service, please kindly report it to Dr. Sun and Dr. Zhang.